Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ...

Fintel reports that on February 11, 2025, Goldman Sachs initiated coverage of Silence Therapeutics plc - Depositary Receipt ( ...

OLX75016: A GWAS-derived therapeutic targeting MASH, liver fibrosis, and other cardiometabolic indications SEONGNAM, South Korea I 10, 2025 I OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...

Wave Life Sciences (WVE) announced clinical trial application, CTA, approval and initiation of the Phase 1 INLIGHT clinical trial of WVE-007 in ...

马萨诸塞州剑桥 - 市值18.7亿美元的临床阶段生物科技公司Wave Life Sciences Ltd. (NASDAQ: WVE )宣布启动WVE-007肥胖治疗的INLIGHT一期临床试验。WVE-007是一种新型GalNAc偶联小干扰RNA ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

来自肠道微生物嗜粘菌Akkermansia muciniphila的66种糖活性酶的生化表征表明，这些酶可以分解一系列宿主聚糖，包括粘蛋白，并将其降解至完全。